Ventus Raises $100m To Take First Novel Compounds Into Clinic
Company Quiet About Initial Targets, Except For NLRP3
Ventus raised $60m in series A venture capital 10 months ago when it had just one technology platform. It now has two platforms, five drug development programs and $100m in series B cash.
You may also be interested in...
Ventus Therapeutics raised a $140m series C while Endeavor Biomedicines brought in $101m in series B cash. Also, Twist Bioscience grossed $250m in a follow-on offering, BioMarin raised $110m when it sold a priority review voucher and Nuvectis, TC BioPharm launched IPOs.
The company doubled its series A total of $51m to not only test its coronavirus and RSV candidates, but to also advance a vaccine targeting both RSV and hMPV for pneumonia prevention in elderly adults.
The cancer drug developer raised $55m. Also, Lyra raised $56m in the last of four biopharma IPOs in April, Biogen sold $3bn worth of debt, Oberland raised a $1.05bn fund and Praxis launched with more than $100m.